{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:25:34Z","timestamp":1761708334909},"reference-count":17,"publisher":"BMJ","issue":"6842","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1992,6,20]]},"DOI":"10.1136\/bmj.304.6842.1621","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T12:16:37Z","timestamp":1238415397000},"page":"1621-1623","source":"Crossref","is-referenced-by-count":4,"title":["Current issues in cancer. Biological therapy."],"prefix":"10.1136","volume":"304","author":[{"given":"T.","family":"Perren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Selby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0167-8140(91)90119-2","article-title":"Biological therapies","volume":"20","author":"Jones, A.; Selby, P.","year":"1991","unstructured":"Jones A, Selby P. Biological therapies. Radiother Oncol 1991;20:211-23.","journal-title":"Radiother Oncol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans-immunotherapy ofmelanoma using tumour-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg, S.A.; Aebersold, P.; Cornetta, K.; Kasid, A.; Morgan, R.A.; Moen, R.","year":"1990","unstructured":"Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R. Gene transfer into humans-immunotherapy ofmelanoma using tumour-infiltrating lymphocytes modified by retroviral gene transduction. N EnglJ7 Med 1990;323:570-3.","journal-title":"N EnglJ7 Med"},{"key":"ref_3","article-title":"Biologic therapy of cancer","author":"V, De Vita","year":"1991","unstructured":"De Vita V, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: J B Lippincott, 1991.","journal-title":"Philadelphia: J B Lippincott"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.1991.9.10.1806","article-title":"Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma. An Eastern Cooperative Oncology Group study","volume":"9","author":"Wadler, S.; Lambersky, B.; Atkins, M.; Kirkwood, J.; Petrelli, N.","year":"1991","unstructured":"Wadler S, Lambersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma. An Eastern Cooperative Oncology Group study. JI Clin Oncol 1991;9:1806-10.","journal-title":"JI Clin Oncol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","article-title":"Remission induction in non-Hodgkin lymphoma with re-shaped human monoclonal antibody CAMPATH-1H","volume":"ii:","author":"Hale, G.; Clark, M.R.; Marcus, R.","year":"1988","unstructured":"Hale G, Clark MR, Marcus R. Remission induction in non-Hodgkin lymphoma with re-shaped human monoclonal antibody CAMPATH-1H. Lancet 1988;ii: 1394-9.","journal-title":"Lancet"},{"key":"ref_6","first-page":"7893","article-title":"Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumour cells","volume-title":"of neuroectodermal origin. Proc NatAcad Sci USA","volume":"83","author":"Honsik, C.J.; Jung, G.; Reisfeld, R.A.","year":"1986","unstructured":"Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumour cells of neuroectodermal origin. Proc NatAcad Sci USA 1986;83:7893-7."},{"key":"ref_7","first-page":"5883","article-title":"Active specific immunotherapy for melanoma: phase I trial ofallogenic lysates and a novel adjuvant","volume":"48","author":"Mitchell, M.S.; Kan-Mitchell, J.; Kempf, R.A.; Harel, W.; Shau, H.Y.; Lind, S.","year":"1988","unstructured":"Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial ofallogenic lysates and a novel adjuvant. Cancer Res 1988;48:5883.","journal-title":"Cancer Res"},{"key":"ref_8","article-title":"A review of patients treated by continuous infusion of recombinant interleukin-2 (rlL-2) with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma","author":"Palmer, P.A.; Vinke, J.; Evers, P.","unstructured":"Palmer PA, Vinke J, Evers P. A review of patients treated by continuous infusion of recombinant interleukin-2 (rlL-2) with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. EurJ Cancer (in press).","journal-title":"EurJ Cancer"},{"key":"ref_9","first-page":"299303","article-title":"The cytokine network","volume":"10","author":"Balkwill, F.; Burke, F.","year":"1989","unstructured":"Balkwill F, Burke F. The cytokine network. Immunology Today 1989;10:299303.","journal-title":"Immunology Today"},{"key":"ref_10","first-page":"247","article-title":"Interferons alfa, beta and gamma; basic principles and pre-clinical studies","author":"Kurzrock, R.; Gutterman, J.U.; Talpay, M.","year":"1991","unstructured":"Kurzrock R, Gutterman JU, Talpay M. Interferons alfa, beta and gamma; basic principles and pre-clinical studies. In: De Vita V, Hellman S, Rosenberg SA, eds. Biologic Therapy ofCancer. Philadelphia: J B Lippincott, 1991:247-74.","journal-title":"Biologic Therapy ofCancer. Philadelphia: J B Lippincott"},{"issue":"6","key":"ref_11","first-page":"678","article-title":"Alfa interferon in hairy cell leukaemia: a five year follow up in 100 patients","volume":"1988","author":"Queseda, JR, Itri; L, Gutterman; J.U.","unstructured":"Queseda JR, Itri L, Gutterman JU. Alfa interferon in hairy cell leukaemia: a five year follow up in 100 patients. Journal of International Research 1988;6:678-85.","journal-title":"Journal of International Research"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with alfa-2b recombinant interferon significantiy improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. Results of an Italian randomised study","volume":"322","author":"Mandelli, F.; Avvisati, G.; Amadori, S.; Boccadoro, M.; Genong, A.; Lauta, V.M.","year":"1990","unstructured":"Mandelli F, Avvisati G, Amadori S, Boccadoro M, Genong A, Lauta VM. Maintenance treatment with alfa-2b recombinant interferon significantiy improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. Results of an Italian randomised study. N EngljMed 1990;322:1430-4.","journal-title":"N EngljMed"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","article-title":"Hematologic remission and cytogenetic improvement induced by recombinant human interferon alfa in chronic myelogenous leukaemia","volume":"314","author":"Talpaz, M.; Kantarjian, H.M.; McCredie, K.B.; Trijillo, J.M.; Keating, M.J.; Guttermang, J.W.","year":"1986","unstructured":"Talpaz M, Kantarjian HM, McCredie KB, Trijillo JM, Keating MJ, Guttermang JW. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alfa in chronic myelogenous leukaemia. N EnglJ Med 1986;314:1065.","journal-title":"N EnglJ Med"},{"key":"ref_14","first-page":"817","article-title":"Tumour necrosis factor: clinical relevance","volume":"8","author":"Jones, A.L.; Selby, P.","year":"1989","unstructured":"Jones AL, Selby P. Tumour necrosis factor: clinical relevance. Cancer Surv 1989;8:817-36.","journal-title":"Cancer Surv"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer","volume":"325","author":"Crawford, J.; Ozer, H.; Stoller, R.; Johnson, D.; Lyman, G.; Tabbara, I.","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164-70.","journal-title":"N Engl J Med"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0277-5379(91)90039-G","article-title":"Emerging clinical uses for GM-CSF","volume":"27","author":"Scarffe, J.H.","year":"1991","unstructured":"Scarffe JH. Emerging clinical uses for GM-CSF. Eur J Cancer 1991;27: 1493-504.","journal-title":"Eur J Cancer"},{"key":"ref_17","first-page":"1871","article-title":"Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia","volume":"323","author":"Ohno, R.; Tomonaga, M.; Kobayashi, T.; Kanamaru, A.; Shirakawa, S.; Masauka, T.","year":"1990","unstructured":"Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masauka T. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N EnglJ Med 1990;323: 1871-77.","journal-title":"N EnglJ Med"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.304.6842.1621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T10:53:15Z","timestamp":1601117595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.304.6842.1621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,6,20]]},"references-count":17,"journal-issue":{"issue":"6842","published-print":{"date-parts":[[1992,6,20]]}},"URL":"https:\/\/doi.org\/10.1136\/bmj.304.6842.1621","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,6,20]]}}}